Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ppul.26292 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial.
Nat Med
March 2025
Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
Antibody-drug conjugates (ADCs) have emerged as a transformative modality in the treatment of solid tumors. YL201, a novel B7H3-targeting ADC, leverages a tumor microenvironment activable linker-payload platform, coupled with a novel topoisomerase 1 inhibitor via a protease-cleavable linker. Here we report the findings from a large-scale, global, multicenter, phase 1 trial evaluating the safety, pharmacokinetics and preliminary efficacy of YL201 in patients with advanced solid tumors refractory to standard therapies.
View Article and Find Full Text PDFGastroesophageal Reflux is a Risk Factor for the Development of de novo Donor Specific Antibodies after Lung Transplantation.
J Heart Lung Transplant
March 2025
Toronto Lung Transplant Program, Ajmera Transplant Centre, University Health Network, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address:
Background: Despite evidence that gastroesophageal reflux (GER) is harmful to the lung allograft, the mechanism of injury remains incompletely defined. We hypothesized that GER induces a humoral alloimmune response and examined the association between GER and de novo donor-specific antibody (DSA) development.
Methods: 508 lung transplant recipients who underwent routine pH-impedance testing at 3 months post-transplant were included.
Dosimetry and Toxicity Comparison of Three-Dimensional Conformal Radiation Therapy and Intensity-Modulated Radiation Therapy in Locally Advanced Lung Cancer Across a Large Statewide Quality Collaborative.
Int J Radiat Oncol Biol Phys
March 2025
Department of Radiation Oncology, University of Michigan, Ann Arbor, MI. Electronic address:
Purpose/objective(s): Use of intensity-modulated radiation therapy (IMRT) versus three-dimensional conformal external beam radiation therapy (3D-CRT) for definitive chemoradiation therapy (CRT) in locally advanced non-small cell lung cancer (LA-NSCLC) has been associated with decreased late pneumonitis, decreased high dose to the heart (itself associated with improved overall survival), and improved patient quality of life. In a statewide radiation oncology quality consortium, we sought to evaluate the impact of IMRT versus 3D-CRT treatment technique on dosimetry and toxicity.
Materials/methods: From 2012 to 2022, 1746 LA-NSCLC patients meeting inclusion criteria underwent definitive RT (90% CRT) with either 3D-CRT (n=313) or IMRT (n=1433) and were enrolled in the [quality consortium] prospective, multicenter statewide initiative.
CENP-H as a new prognostic biomarker for tumors: a real-world literature review.
Front Oncol
February 2025
Department of Thoracic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Centromere protein H (CENP-H) is an important component of a functional centromere. Studies have demonstrated that CENP-H is overexpressed in renal cell, gastric, hypopharyngeal squamous cell, nasopharyngeal, endometrial, lung, cervical, esophageal, liver, colorectal, oral squamous cell, breast, and tongue carcinomas. CENP-H overexpression is positively correlated with a poor prognosis, pathological stage, T stage, and lymph node metastasis in patients with the above carcinomas.
View Article and Find Full Text PDFTiming of thoracic radiotherapy combined with immunotherapy influences pulmonary injury.
Oncol Lett
April 2025
Department of Radiation Oncology, Beijing Luhe Hospital, Capital Medical University, Beijing 101100, P.R. China.
The present study aimed to assess the impact of chest radiotherapy combined with immunotherapy at different time points in lung injury. This retrospective study analyzed 35 patients with thoracic tumors (29 lung cancer cases and 6 esophageal cancer cases) who received radiotherapy combined with immunotherapy between January 2021 and December 2023 at at Capital Medical University, affiliated with Beijing Luhe Hospital (Beijing, China), with a median follow-up time of 21 months. Patients were divided into two groups: Group A (sequential, n=17), who received immunotherapy 2 weeks to 6 months before or after radiotherapy, and group B (synchronous, n=18), who received immunotherapy within 2 weeks before or after radiotherapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!